CRTX News and Press, Cortexyme Inc. From 10/27/21

Shares of Cortexyme (NASDAQ: CRTX) , a clinical-stage biotechnology company, are collapsing in response to a clinical trial failure. Investors upset with the results had hammered the stock 74.9% lower as of 12:14 p.m. EDT on Wednesday. Cortexyme's former lead candidate, atuzagin...

Gainers: G Medical Innovations (NASDAQ:GMVD) +18%, Guardion Health Sciences (NASDAQ:GHSI) +12%, Nurix Therapeutics NRIX +11%, Privia Health (NASDAQ:PRVA) +8%, Monopar Therapeutics MNPR +7%. Losers: Cortexyme (NASDAQ:CRTX) -75%, BIMI Inter...

Gainers: Enphase Energy ENPH +12%. Tenable Holdings TENB +10%. Aware AWRE +8%. Marqeta MQ +6%. EVgo (NASDAQ:EVGOW) +583%. Losers: Cortexym CRTX -72%. Angion Biomedica ANGN -56%. DBV Technologies DBVT -28%. Redbox Entertainment (NASDAQ:RDBXW) -16%. ...

In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Clinical data validated ...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P 500 wrapped up its best week since July, closing at its highest level in a month, as a series of upside earnings reports from Wal...

Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed. Small Pharma Analyst shares a lon...

While the S&P 500 index added ~1.8% gain over the week, its healthcare constituents underperformed with a ~0.8% rise yet, recording their first weekly gain in more than a month. Dragged down by pharma stocks, the sector became the second-worst performer in the index for ano...

Cortexyme has a unique hypothesis- that Alzheimer’s disease (AD) is caused by a neurological infection with P. gingivalis. There is a surprising amount of data generated by the company and independent labs supporting this hypothesis. The stock will likely soar if the GAIN t...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14 th Clinical Trials on Alzheimer's Disease (CTAD 2...

CRTX is pursuing a highly speculative hypothesis that gingivitis plays a role in the pathogenesis of Alzheimer's Disease (AD). Top line results for AD Phase 2/3 trial expected mid-November; success would be one of the greatest medical breakthroughs in modern history. Success in a ...